Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1994 Mar;37(3):243–248. doi: 10.1111/j.1365-2125.1994.tb04270.x

Pharmacokinetics of rac-leucovorin vs [S]-leucovorin in patients with advanced gastrointestinal cancer.

R M Mader 1, G G Steger 1, B Rizovski 1, A E Sieder 1, G Locker 1, M F Gnant 1, R Jakesz 1, H Rainer 1
PMCID: PMC1364754  PMID: 8198932

Abstract

1. The pharmacokinetics of [R]-leucovorin ([R]-LV), [S]-leucovorin ([S]-LV) and the circulating metabolite [S]-5-methyltetrahydrofolate ([S]-5-MTHF) were studied after administration of racemic LV and [S]-LV in 21 subjects. 2. After intravenous infusion of 600 mg m-2 rac-LV (group 1, n = 7) or 300 mg m-2 [S]-LV (group 3, n = 7), the decay of [S]-LV in plasma was biexponential with a distribution half-life of 0.8 to 1 h and an elimination half-life of 11 to 23 h. When rac-LV was administered as a 2 h i.v. infusion (400 mg m-2) following a loading dose of 200 mg m-2 (group 2, n = 7), the plasma concentrations of [R]-LV and [S]-5-MTHF decayed monoexponentially with mean (+/- s.d.) half-lives of 10 +/- 3 h and 7 +/- 2 h, respectively. 3. The AUC of [S]-5-MTHF was significantly higher after infusion of 300 mg m-2 [S]-LV than after infusion of 600 mg m-2 rac-LV (83 +/- 22 micrograms ml-1 h vs 53 +/- 22 micrograms ml-1 h; P = 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
243

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arbuck S. G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer. 1989 Mar 15;63(6 Suppl):1036–1044. doi: 10.1002/1097-0142(19890315)63:6+<1036::aid-cncr2820631309>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  2. Berger S. H., Hakala M. T. Relationship of dUMP and free FdUMP pools to inhibition of thymidylate synthase by 5-fluorouracil. Mol Pharmacol. 1984 Mar;25(2):303–309. [PubMed] [Google Scholar]
  3. Bertrand R., Jolivet J. Lack of interference by the unnatural isomer of 5-formyltetrahydrofolate with the effects of the natural isomer in leucovorin preparations. J Natl Cancer Inst. 1989 Aug 2;81(15):1175–1178. doi: 10.1093/jnci/81.15.1175. [DOI] [PubMed] [Google Scholar]
  4. Bleyer W. A. New vistas for leucovorin in cancer chemotherapy. Cancer. 1989 Mar 15;63(6 Suppl):995–1007. doi: 10.1002/1097-0142(19890315)63:6+<995::aid-cncr2820631302>3.0.co;2-r. [DOI] [PubMed] [Google Scholar]
  5. Branda R. F., Anthony B. K., Jacob H. S. The mechanism of 5-methyltetrahydrofolate transport by human erythrocytes. J Clin Invest. 1978 May;61(5):1270–1275. doi: 10.1172/JCI109043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Choi K. E., Schilsky R. L. Resolution of the stereoisomers of leucovorin and 5-methyltetrahydrofolate by chiral high-performance liquid chromatography. Anal Biochem. 1988 Feb 1;168(2):398–404. doi: 10.1016/0003-2697(88)90335-1. [DOI] [PubMed] [Google Scholar]
  7. Evans R. M., Laskin J. D., Hakala M. T. Effect of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. 1981 Sep;41(9 Pt 1):3288–3295. [PubMed] [Google Scholar]
  8. Houghton J. A., Williams L. G., Cheshire P. J., Wainer I. W., Jadaud P., Houghton P. J. Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts. Cancer Res. 1990 Jul 1;50(13):3940–3946. [PubMed] [Google Scholar]
  9. Houghton J. A., Williams L. G., de Graaf S. S., Cheshire P. J., Rodman J. H., Maneval D. C., Wainer I. W., Jadaud P., Houghton P. J. Relationship between dose rate of [6RS]Leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res. 1990 Jun 15;50(12):3493–3502. [PubMed] [Google Scholar]
  10. Lee P. P., Schilsky R. L. Inhibition of thymidylate synthase by the diastereoisomers of leucovorin. Cancer Chemother Pharmacol. 1990;26(4):273–277. doi: 10.1007/BF02897229. [DOI] [PubMed] [Google Scholar]
  11. Machover D., Goldschmidt E., Chollet P., Metzger G., Zittoun J., Benavides M., Marquet J., Vandenbulcke J. M., Misset J. L., Schwarzenberg L. Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. NCI Monogr. 1987;(5):193–198. [PubMed] [Google Scholar]
  12. Morgan R. G. Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase. Cancer. 1989 Mar 15;63(6 Suppl):1008–1012. doi: 10.1002/1097-0142(19890315)63:6+<1008::aid-cncr2820631303>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  13. Patel R., Newman E. M., Villacorte D. G., Sato J. K., Reaman G. H., Finklestein J. Z., Krailo M. D., Hammond G. D., Holcenberg J. S. Pharmacology and phase I trial of high-dose oral leucovorin plus 5-fluorouracil in children with refractory cancer: a report from the Children's Cancer Study Group. Cancer Res. 1991 Sep 15;51(18):4871–4875. [PubMed] [Google Scholar]
  14. Peters G. J., van Groeningen C. J., van der Wilt C. L., Meijer S., Smid K., Laurensse E., Pinedo H. M. Time course of inhibition of thymidylate synthase in patients treated with fluorouracil and leucovorin. Semin Oncol. 1992 Apr;19(2 Suppl 3):26–35. [PubMed] [Google Scholar]
  15. Schilsky R. L., Ratain M. J. Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst. 1990 Sep 5;82(17):1411–1415. doi: 10.1093/jnci/82.17.1411. [DOI] [PubMed] [Google Scholar]
  16. Shumaker R. C. PKCALC: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev. 1986;17(3-4):331–348. doi: 10.3109/03602538608998295. [DOI] [PubMed] [Google Scholar]
  17. Straw J. A., Covey J. M., Szapary D. Differences in the pharmacokinetics of the diastereoisomers of citrovorum factor in dogs. Cancer Res. 1981 Oct;41(10):3936–3939. [PubMed] [Google Scholar]
  18. Trave F., Rustum Y. M., Petrelli N. J., Herrera L., Mittelman A., Frank C., Creaven P. J. Plasma and tumor tissue pharmacology of high-dose intravenous leucovorin calcium in combination with fluorouracil in patients with advanced colorectal carcinoma. J Clin Oncol. 1988 Jul;6(7):1184–1191. doi: 10.1200/JCO.1988.6.7.1184. [DOI] [PubMed] [Google Scholar]
  19. Wilson S. D., Horne D. W. Evaluation of ascorbic acid in protecting labile folic acid derivatives. Proc Natl Acad Sci U S A. 1983 Nov;80(21):6500–6504. doi: 10.1073/pnas.80.21.6500. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Zhang Z. G., Rustum Y. M. Effects of diastereoisomers of 5-formyltetrahydrofolate on cellular growth, sensitivity to 5-fluoro-2'-deoxyuridine, and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells. Cancer Res. 1991 Jul 1;51(13):3476–3481. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES